Urinary zinc excretion in recurrent calcareous nephrolithiasis (RCN) patients

M. Surian, G. Graziani, G. Colussi, A. Antonacci, A. Aroldi, M. Giacchetti, F. Masi, G. Civati, L. Minetti

Research output: Contribution to journalArticlepeer-review


Urinary (ZnE, μg/100 ml GFR) and plasma (PZn, μg/dl) zinc (Zn) were determined during an oral calcium tolerance test in 33 RCN patients (26 with idiopathic hypercalciuria, of the renal (R) type in 14, absorptive (A) in 9, tubulophosphaturic in 3; 3 with hyperparathyroid resorptive hypercalciuria, and 4 with normocalciuria), and in 17 normal subjects (N). PZn and basal ZnE were not significantly different either in RCN patients, or in R and A hypercalciurics from N. ZnE did not change after calcium load in comparison with basal levels both in N and in RCN patients. No correlation was found between basal or after load ZnE and CaE both in N and in RCN. In 12 of the hypercalciuric patients 25-50 mg/day of hydrochlorothiazide significantly increased, after 6 months of therapy, urinary Zn excretion (UZnV, μg/day) and the UZn/UCa ratio, which had been below normal values before treatment: this was due both to the reduction of calcium excretion and to the increase in UZnV. Urinary Zn excretion and the UZn/UCa ratio, may be better indexes of thiazide therapy efficacy than calcium excretion alone.

Original languageEnglish
Pages (from-to)537-542
Number of pages6
JournalMinerva Nefrologica
Issue number4
Publication statusPublished - 1979

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Urinary zinc excretion in recurrent calcareous nephrolithiasis (RCN) patients'. Together they form a unique fingerprint.

Cite this